WO2004019821A1 - Medical devices and methods of making the same - Google Patents

Medical devices and methods of making the same Download PDF

Info

Publication number
WO2004019821A1
WO2004019821A1 PCT/US2003/024302 US0324302W WO2004019821A1 WO 2004019821 A1 WO2004019821 A1 WO 2004019821A1 US 0324302 W US0324302 W US 0324302W WO 2004019821 A1 WO2004019821 A1 WO 2004019821A1
Authority
WO
WIPO (PCT)
Prior art keywords
endoprosthesis
fibers
polymer
tubular member
oriented
Prior art date
Application number
PCT/US2003/024302
Other languages
French (fr)
Inventor
Jonathan S. Stinson
Original Assignee
Boston Scientific Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Scientific Limited filed Critical Boston Scientific Limited
Priority to EP03791634.3A priority Critical patent/EP1545394B1/en
Priority to AU2003261349A priority patent/AU2003261349B2/en
Priority to JP2004532853A priority patent/JP2005537090A/en
Priority to CA2496576A priority patent/CA2496576C/en
Publication of WO2004019821A1 publication Critical patent/WO2004019821A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/88Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/89Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/075Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0096Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
    • A61F2250/0098Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/24Structurally defined web or sheet [e.g., overall dimension, etc.]
    • Y10T428/24058Structurally defined web or sheet [e.g., overall dimension, etc.] including grain, strips, or filamentary elements in respective layers or components in angular relation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/24Structurally defined web or sheet [e.g., overall dimension, etc.]
    • Y10T428/24058Structurally defined web or sheet [e.g., overall dimension, etc.] including grain, strips, or filamentary elements in respective layers or components in angular relation
    • Y10T428/24074Strand or strand-portions
    • Y10T428/24091Strand or strand-portions with additional layer[s]
    • Y10T428/24099On each side of strands or strand-portions
    • Y10T428/24107On each side of strands or strand-portions including mechanically interengaged strands, strand-portions or strand-like strips

Definitions

  • the invention relates to medical devices, such as, for example, endoprostheses, and methods of making the devices.
  • the body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis.
  • An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprosthesis include stents and covered stents, sometimes called "stent-grafts".
  • Endoprostheses can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
  • the expansion mechanism may include forcing the endoprosthesis to expand radially.
  • the expansion mechanism can include the catheter carrying a balloon, which carries a balloon expandable endoprosthesis.
  • the balloon can be inflated to deform and to fix the expanded endoprosthesis at a predetermined position in contact with the lumen wall.
  • the balloon can then be deflated, and the catheter withdrawn.
  • a self-expandable endoprosthesis is formed of an elastic material that can be reversibly compacted and expanded, e.g., elastically or through a material phase transition.
  • the endoprosthesis is restrained in a compacted condition on a catheter.
  • the restraint is removed, for example, by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force.
  • endoprostheses can be made of relatively stiff and strong materials, such as stainless steel or Nitinol (a nickel-titanium alloy), that can resist compression and/or dislocation of the endoprostheses.
  • the physical or mechanical properties of the endoprosthesis materials however, sometimes do not closely match those properties of the body vessel, which is relatively compliant and resilient. The mismatch in properties, and the presence of the endoprosthesis (a foreign object) in the body, can cause the vessel to become inflamed and/or re-occluded.
  • the invention relates to medical devices, such as, for example, endoprostheses, and methods of making the devices.
  • the invention features endoprostheses that have physical and mechanical properties (e.g., resiliency or compliancy) similar to those of a body vessel, thereby reducing the occurrence of inflammation and/or re-occlusion.
  • the endoprostheses have good radial and/or hoop strengths, e.g., to maintain the body vessel open and to resist dislodgement after implantation.
  • the endoprostheses are formed of a composite including a polymer.
  • the invention features an endoprosthesis having a tubular member including a polymer matrix and a plurality of fibers in the matrix.
  • the fibers have a stiffness greater than the stiffness of the polymer and are substantially oriented in a predetermined direction.
  • the fibers can be oriented substantially circumferentially, longitudinally, and/or radially relative to a longitudinal axis of the tubular member.
  • Embodiments may include one or more of the following features.
  • the fibers include a metal (such as gold, tantalum, platinum, or tungsten) and/or a polymer.
  • the fibers are dispersed throughout substantially the entire matrix.
  • the fibers are formed on preselected portions of the tubular member.
  • the fibers extend helically around the tubular member.
  • the fibers are formed in a configuration that enhances the radial, hoop, and/or longitudinal strength of the tubular member.
  • the fibers have a first end that is larger than a second end.
  • the fibers are visible by magnetic resonance imaging.
  • the endoprosthesis further includes a magnetopaque material different than the fibers in the matrix.
  • the tubular member can be formed of a plurality of polymeric layers.
  • the plurality of polymeric layers can include a layer having fibers oriented substantially longitudinally relative to the tubular member, and a layer having fibers oriented substantially radially or circumferentially relative to the tubular member.
  • the endoprosthesis can further include a drug-releasing layer on the tubular member.
  • the matrix can include a drug.
  • the endoprosthesis can be in the form of a balloon-expandable stent.
  • the invention features an endoprosthesis including a tubular member having a polymer, and a first member extending helically around the tubular member.
  • the first member has a stiffness greater than stiffness of the polymer.
  • Embodiments may include one or more of the following features.
  • the first member includes a metal and/or a polymer.
  • the tubular member includes a plurality of fibers in the polymer that has a stiffness greater than the stiffness of the polymer and is substantially oriented in a predetermined direction.
  • the polymer encapsulates the first member.
  • the invention features a endoprosthesis having a tubular member having a first layer including a first polymer, and a second layer including a second polymer and a plurality of fibers in the second polymer.
  • the fibers have a stiffness greater than the stiffness of the polymer and are oriented in a predetermined direction.
  • Embodiments may include one or more of the following features.
  • the first layer further includes a plurality of fibers oriented in a predetermined direction.
  • the pluralities of fibers in the first and second layers are substantially the same.
  • the pluralities of fibers in the first and second layers are oriented in different directions.
  • the pluralities of fibers in the first and second layers are oriented in the same direction.
  • the first and second polymers are the same polymer.
  • Embodiments may further include one or more of the following advantages.
  • the medical devices are relatively compatible with magnetic resonance imaging (MRI).
  • MRI magnetic resonance imaging
  • the devices can be resected, e.g., after implantation.
  • the devices are relatively resistant to fracture.
  • FIG. 1 is an illustration an embodiment of an endoprosthesis
  • FIG. 2 is an illustration an embodiment of an endoprosthesis
  • FIG. 3 is an illustration an embodiment of an endoprosthesis
  • FIG. 4 is an illustration an embodiment of an endoprosthesis
  • FIG. 5 is an illustration an embodiment of a method of making the endoprosthesis of Fig. 1;
  • Fig. 6 is an illustration an embodiment of a method of making an endoprosthesis;
  • Fig. 7 is an illustration an embodiment of a method of making an endoprosthesis;
  • Fig. 8 is an illustration an embodiment of a method of making an endoprosthesis;
  • Fig. 9 is an illustration of an embodiment of a tubular member;
  • Fig. 10 is an illustration of an embodiment of a device for making an endoprosthesis.
  • Fig. 1 shows an endoprosthesis 22, here, a slotted tube stent, including a tubular member 23 formed of a matrix of polymer 24 and a plurality of fibers 26 preferentially oriented in a predetermined direction within the matrix.
  • the polymer provides endoprosthesis 22 with mechanical properties, such as resiliency and compliancy, that match well with the mechanical properties of a body vessel. As a result, the occurrence of inflammation and/or re-occlusion can be reduced.
  • Fibers 26 are formed of a material, such as a metal, that is stiffer than the polymer and can reinforce matrix 24. As shown in Fig. 1, fibers 26 are oriented circumferentially (arrow A) around tubular member 23. As a result, fibers 26 can enhance the hoop strength of tubular member 23, which helps endoprosthesis 22 to resist compression, thereby maintaining the body vessel open.
  • fibers 26 are oriented in one or more directions to strengthen matrix 24 (e.g., relative to the matrix with the fibers) along the loading axes of endoprosthesis 22, such as in the radial and/or hoop direction.
  • an endoprosthesis 42 includes fibers 26 that are oriented radially (arrow B) to enhance the radial strength of the endoprosthesis.
  • Fibers 26 can be oriented longitudinally, i.e., parallel to the length of the endoprosthesis, which can enhance axial stiffness.
  • an endoprosthesis is formed of multiple layers, e.g., greater than or equal to two, three, four, five or six layers.
  • the layers can be the same or different relative to each other, e.g., with respect to the type and/or composition of polymer(s) and/or fiber, the amount of fiber in each layer, and/or the orientation of the fibers.
  • a multilayer endoprosthesis may include one or more layers having fibers that are oriented radially, one or more layers having fibers that are oriented circumferentially, and/or one or more layers having no fibers, which can enhance the compliancy and resiliency of the endoprosthesis.
  • the layers can have the same or different thickness.
  • an endoprosthesis may include layers of radially oriented fibers alternating with layers of circumferentially oriented fibers (Fig. 3).
  • the layers can be grouped together, e.g., the layers with radially oriented fibers can be the inner layers and the layers with circumferentially oriented fibers can be the outer layers, or vice versa (Fig. 4).
  • a method 20 of making endoprosthesis 22 having circumferentially oriented fibers 26 generally includes forming a polymeric sheet 28 having the fibers oriented parallel to longitudinal axis C of the sheet.
  • Methods of making sheet 28 include, for example, forming a mixture of the polymer of matrix 24 and fibers 26, and pultruding the mixture. Pultrusion is described in, for example, C. A. Harper, Handbook of Plastics and Elastomers, McGraw-Hill Book Co., New York 1975, 5-88 to 5-89, hereby incorporated by reference.
  • sheet 28 can be formed by positioning, e.g., laying flat, fibers 26 in a desired orientation in a mold. The matrix polymer can then be introduced into the mold in a solid or liquid state. Heat and/or pressure are then applied to allow the polymer to encapsulate the fibers.
  • Sheet 28 can then be wound, e.g., circumferentially, around a mandrel, and opposing edges 30 of the sheet can be joined together, e.g., by welding or by an adhesive, to form tubular member 23.
  • Tubular member 23 can be drawn and/or cut to size, as needed, and portions of the tubular member are removed to form openings 32 of endoprosthesis 22.
  • Endoprosthesis 22 can be cut and/or formed by laser cutting, as described in U.S. Patent No. 5,780,807, hereby incorporated by reference in its entirety.
  • a plurality of sheets 28 can be laminated together, e.g., using an adhesive or by heat bonding, and wrapped around a mandrel to form tubular member 23 and endoprosthesis 22.
  • the orientation of fibers 26 may change from their initial orientation when the endoprosthesis is expanded during use.
  • an endoprosthesis 34 can be formed in which strips of sheet 28 are wound, e.g., helically, at a predetermined initial angle around the mandrel.
  • strips 28 and fibers 26 can orient to a desired final orientation, e.g., substantially circumferentially and perpendicular to longitudinal axis D of endoprosthesis 34.
  • the initial winding angle of strips 28 can be, for example, from about 5 to about 85 degrees relative to axis D. Adjacent edges of strips 28 can be joined together, for example, by gluing the edges and/or selectively melting and re-solidifying the edges.
  • a method 40 of making endoprosthesis 42 having radially oriented fibers 26 includes forming a polymeric sheet 46 in which the fibers are oriented perpendicular to longitudinal axis E of the sheet. After sheet 46 with oriented fibers 44 is formed, the sheet can be formed into endoprosthesis 42 as described above. For example, sheet 46 or strips of the sheet can be wound, e.g., circumferentially or helically, around a mandrel, and edges of the sheet can be bonded together to form a tubular member. The tubular member can then be formed into endoprosthesis 42, e.g., by laser cutting. As shown in Fig. 7, multiple sheets 46 are laminated together, and the multilayer laminate can be wound around the mandrel and formed into endoprosthesis 42.
  • Fibers 26 can be manually pressed into an unsolidified sheet of polymer, and/or the fibers can be sprayed into an unsolidified sheet of polymer using a spray nozzle with an appropriate size and geometry.
  • Fibers 26 can be formed having a first end heavier than a second end, e.g., by forming a stub on the first end or by tapering the size of the fiber. The fibers are then placed into an unsolidified sheet of polymer. The heavier ends of the fibers tend to align the fibers perpendicular to longitudinal axis E of sheet 46.
  • asymmetrical fibers e.g., those having one end heavier than another end
  • the matrix polymer can be mixed with the matrix polymer and spin casted (e.g., about the longitudinal axis) in a mold to form a tubular member.
  • the centrifugal force generated during spin casting can orient the fibers in the polymer, e.g., the fibers can orient radially, with the heavier ends outward of the lighter ends.
  • magnetic fibers 26, e.g., ferromagnetic or paramagnetic fibers, such as 300 series stainless steel can be oriented by placing an unsolidified sheet having the fibers in a magnetic field such that the magnetic flux lines are perpendicular to longitudinal axis E of the sheet.
  • the magnetic flux lines may be non-perpendicular to longitudinal axis E to orient fibers 26 in a desired initial orientation.
  • a multilayer endoprosthesis in which the layers are different can be made by winding a sheet of polymer (with or without fibers) around a preformed tubular member.
  • the innermost layer can be formed by method 20 to form tubular member 23.
  • Sheet 46 can then be wrapped and secured around tubular member 23.
  • a second sheet 28 can then be wound around and secured to sheet 46.
  • close fitting tubular members (with or without fibers) having an adhesive material between the tubular members can be co-drawn to form a multilayer endoprosthesis.
  • the polymer used in the endoprostheses described herein can be any polymer that is biocompatible.
  • the polymer preferably has acceptable vascular compatibility, e.g., relatively low thrombogenecity and low cytotoxicity.
  • the polymer is preferably stable in various bodily fluids.
  • the polymer can be biodegradable, for example, if the polymer is used for temporary endoprostheses.
  • the polymer can be relatively stiff or hard, e.g., having a hardness of more than about 50 Shore D, such as 72 Shore D or more.
  • the layers may or may not include the same polymer.
  • the difference in hardness of adjacently bonded layers can be about 40 Shore D or less, such as 20 Shore D or less, which can enhance compatibility between the layers, and/or reduce delamination at the interface. Hardness may be measured according to ASTM D2240.
  • the polymer can have an elastic modulus of about 10,000-
  • the elastic modulus can be equal to or greater than about 100,000, 500,000, 1,000,000, or 1,500, 000 psi; and/or equal to or less than 2,000,000, 1,500,000, 1,000,000, 500,000, or 100,000 psi.
  • the polymer can have an elongation to fracture equal to or greater than about 10%, e.g., equal to or greater than about 20%, 30%, 40%, or 50%.
  • the polymer can have a yield strength equal to or greater than about 10,000 psi, e.g., equal to or greater than about 25,000 psi or 50,000 psi.
  • the polymer may be of a substantially pure polymer or may be blends of different polymers.
  • the polymer can be made of block copolymers including common block moieties, which can enhance compatibility, while maintaining defect retardation.
  • the block moieties may be amide segments and tetramethylene glycol segments.
  • An example is the PEBAX® family of polymers, which can be used pure or as blends (available from Atofina, Philadelphia, PA).
  • PEBAX® 5533 55 Shore D
  • PEBAX® 2533 25 Shore D
  • PBT polybutylene terephthalate
  • CELANEX® over 80 Shore D, from Ticona, Summit, NJ
  • polyester/ether block copolymer available as ARNITEL® 55 Shore D, from DSM, Erionspilla, IN
  • PBT and one or more PBT thermoplastic elastomers such as RITEFLEX® (55 Shore D from Ticona in Summit, NJ) and HYTREL® (55 Shore D from E. I. Dupont de Nemours, Wilmington, DE) for example.
  • Still another combination of polymers is polyethylene terephthalate (PET) and a thermoplastic elastomer, such as a PBT thermoplastic elastomer (e.g., ARNITEL®, HYTREL®, or RITEFLEX®).
  • PET polyethylene terephthalate
  • thermoplastic elastomer such as ARNITEL®, HYTREL®, or RITEFLEX®.
  • one or more layers can contain one or more nylons.
  • a combination of polymers is a nylon and a PEBAX®-type material, such as PEBAX®, GRILON®, GRILAMID® (EMS) and/or VESTAMID® (Creanova).
  • nylons include aliphatic nylons, such as Nylon 11 (Elf Atochem), Nylon 6 (Allied Signal), Nylon 6/10 (BASF), Nylon 6/12 (Ashley Polymers) and Nylon 12. Additional examples of nylons include aromatic nylons, such as GRIVORY® (EMS) and Nylon MXD-6. Other nylons and/or combinations of nylons can be used.
  • one or more layers can contain a liquid crystal polymer
  • LCP e.g., a composite material having the LCP incorporated therein.
  • LCPs include polyester(s), polyamide(s) and/or their copolymers, such as NECTRA® A (Ticona), NECTRA® B (Ticona) and VECTRA® LKX (Ticona) (e.g., NECTRA® LKX 1111 (Ticona)).
  • Other LCPs and/or combinations of LCPs can be used.
  • the LCP can be incorporated into one or more polymers, such as, for example, a PEBAX®-type material, a nylon, a thermoplastic polyester and/or thermoplastic elastomer versions thereof.
  • the liquid crystal polymer can be incorporated into one or more of the polymer layers to form a hard layer of material (e.g., a layer of material with more than about 60 Shore D hardness, such as more than about 65 Shore D hardness).
  • an LCP is incorporated into a layer containing one or more PEBAX®-type materials, such as PEBAX®, GRILO ⁇ ®, GRILAMID®, and/or NESTAMID®.
  • an LCP-containing composition can be relatively stiff in the direction of melt flow. Without wishing to be bound by theory, it is believed that this may result because LCP crystals (e.g., fibers) form or align in the melt flow direction as the polymer composite cools from a liquid state to a solid state. It is believed that the LCP fibers can reinforce the other polymer(s) contained in the layer (e.g., matrix polymer(s)).
  • LCP crystals e.g., fibers
  • the LCP fibers can reinforce the other polymer(s) contained in the layer (e.g., matrix polymer(s)).
  • the amount of LCP contained in the tube or balloon can vary depending upon its intended use. In some embodiments, as the percentage of LCP in a composite material is decreased, the individual layer thickness and the overall thickness of one or more layers of an LCP-containing composite material can be increased.
  • the LCP content of a tube can be at least about 0.1 weight percent, such as from about 0.1 weight percent to about 20 weight percent (e.g., from about 0.5 weight percent to about 10 weight percent, from about one to about five weight percent). Within a given layer, the LCP content can be at least about 0.1 weight percent (e.g., from about one weight percent to about 50 weight percent, from about five weight percent to about 20 weight percent, from about five weight percent to about 15 weight percent).
  • an adhesion enhancing material can be incorporated into one or more material layers.
  • An adhesion enhancing material can be used, for example, to enhance the adhesion between adjacent layers.
  • adhesion enhancing materials include epoxy or anhydride modified polyolefms, such as LOTADER® (Elf Atochem) and KODAR® PETG (Eastman Kodak).
  • An adhesion enhancing material can be added to a material (e.g., a composition containing one or more polymers), e.g., prior to molding or pultrusion.
  • PETG can be added to the PET.
  • the amount of adhesion enhancing material can vary depending upon the intended use. In some embodiments, a sufficient amount of adhesion enhancing material(s) are included in the material so that the adhesion enhancing material(s) makes up at least about 0.5 percent of the resulting mixture that forms the layer (e.g., at least about one percent, at least about five percent, at least about 10 percent) and/or at most about 20 percent of the resulting mixture that forms the layer (e.g., at most about 15 percent, at most about 12 percent, at most about 10 percent).
  • a sufficient amount of adhesion enhancing material(s) are included in the material so that the adhesion enhancing material(s) makes up at least about 0.5 percent of the resulting mixture that forms the layer (e.g., at least about one percent, at least about five percent, at least about 10 percent) and/or at most about 20 percent of the resulting mixture that forms the layer (e.g., at most about 15 percent, at most about 12 percent, at most about 10 percent).
  • a compatibilizing material can be incorporated into one or more material layers.
  • the compatibilizing material can be designed, for example, to modify one or more phase boundaries of the LCP(s) and one or more of the other polymer(s) (e.g., thermoplastic polymer(s)) and/or to enhance adhesion between the LCPs and one or more of the other polymer(s).
  • the compatibilizing material can be a copolymer, such as a block copolymer, including moieties of at least two different chemical structures, respectively providing compatibility with an LCP and one or more other polymers in the mixture.
  • the compatibilizing material can be a reactive polymer that reacts with the LCP and/or one or more other polymers in the mixture.
  • the compatibilizing material can be a catalyst that promotes a reaction between the LCP and one or more other polymers in the mixture. Other compatibilizing materials can be used. Combinations of compatibilizing materials can be used.
  • compatibilizing materials include copolyester elastomers, ethylene unsaturated ester copolymers, such as ethylene-maleic anhydride copolymers, copolymers of ethylene and a carboxylic acid or acid derivative, such as ethylene- methyl acrylate copolymers, polyolefms or ethylene-unsaturated ester copolymers grafted with functional monomers, such as ethylene-methyl acrylate copolymers, copolymers of ethylene and a carboxylic acid or acid derivative, such as ethylene- methyl acrylate maleic anhydride terpolymers, terpolymers of ethylene, unsaturated ester and a carboxylic acid or acid derivative, such as ethylene-methyl acrylate- methacrylic acid terpolymers, maleic acid grafted styrene-ethylene-butadiene-styrene block copolymers, and acrylic acid elastomers, such as acrylic rubbers.
  • Similar polymers containing epoxy functional groups for instance derived from glycidyl methylacrylate (e.g., alkyl(meth)acrylate-ethylene-glycidyl (meth)acrylate polymers) can be used.
  • Ionomeric copolymers can be used.
  • PETG can be used.
  • compatibilizing materials include HYTREL® HTR-6108, POLYBOND® 3009 (BP Chemicals), SP 2205 (Chevron), DS 1328/60 (Chevron), LOTADER® 2400, ESCOR® ATX-320, ESCOR® ATX-325, NAMAC® Gl and LOTADER® AX8660.
  • a compatibilizing material e.g., PETG
  • one or more polymers e.g., an LCP-containing material
  • LCP blend can be a ternary system of LCP, thermoplastic and compatibilizing materials. Systems with multiple combinations of different LCPs, different thermoplastics and different compatibilizing materials are contemplated.
  • the compatibilized blend can be a blend of polyazomethine LCP, a thermoplastic polymer such as a polyamide, and a compatibilizing material such as a caprolactum having at least one functional group capable of showing compatibility and/or reactivity to the LCP and/or the thermoplastic polymer.
  • a compatibilizing material such as a caprolactum having at least one functional group capable of showing compatibility and/or reactivity to the LCP and/or the thermoplastic polymer.
  • One polymer blend product which can be used include PET, a wholly aromatic
  • LCP copolyester and an ethylene-methyl acrylate-acrylic acid terpolymer compatibilizing material such as, for example, ESCOR® ATX320, ESCOR® ATX325, or ESCOR® XV-11.04.
  • Another polymer blend product includes PET, a wholly aromatic LCP copolyester and an ethylene-maleic anhydride copolymer compatibilizing material, such as POLYBOND® 3009.
  • Another polymer blend product includes PET, a wholly aromatic LCP copolyester and an ethylene-methyl acrylate copolymer grated with maleic anhydride compatibilizing material, such as DS 1328/60, or a copolyester elastomer, such as HYTREL® HTR 6108.
  • Polymer blend products including PET, LCP and at least two compatibilizing materials can be used.
  • DS 1328/60 and POLYBOND® 3009 can be used with the LCP NECTRA®.
  • the compatibilizing materials can be POLYBOND® 3009 and at least one additional compatibilizing material selected from ESCOR® ATX-320, ESCOR® ATX-325, DS 1328160, ESCOR® XV-11.04 and HYTREL® HTR-6108.
  • consideration is given to the properties of the LCP and the other polymer(s) (e.g., PET), as well as the desired properties of the resulting blend, when selecting the compatibilizing material(s).
  • the blend product includes from about 0.1 weight percent to about 10 weight percent (e.g., from about 0.5 weight percent to about 2 percent) LCP, from about 40 weight percent to about 99 weight percent (e.g., from about 85 weight percent to about 99 weight percent) thermoplastic polymer, and from about 0.1 weight percent to about 30 weight percent (e.g., from about one weight percent to about 10 weight percent) compatibilizing material(s).
  • polymers and polymer combinations are discussed above, other polymers and polymer combinations can also be used.
  • Other polymers include, for example, elastomers such as thermoplastic elastomers and engineering thermoplastic elastomers, such as polybutylene terephthalate-polyethene glycol block copolymers, which are available, for example, as HYTREL®. These are discussed in Hamilton U.S. 5,797,877, the entire content of which is incorporated herein by reference.
  • Other polymers include polyurethenes, polytetrafluoroethylene (PTFE), polylactic acid (PLA), styrene-isobutylene-styrene (SIBS), polypropylene, and polyglycolide.
  • polymers include copolymers such as ABS (acrylonitrile-butadiene-styrene), ABS/nylon, ABSApolyvinyl chloride (PVC), ABS/polycarbonate, acrylonitrile copolymer, polyacrylamide, polyacrylate and polyacrylsulfone, polyesters such as polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyethylene naphthalate (PEN), liquid crystal polymer (LCP), polyester/polycaprolactone and polyester/polyadipate; and high melt temperature polyethers including polyetheretherketone (PEEK), polyethersulfone (PES), polyetherimide (PEI) and polyetherketone (PEK), polymenthylpentene, polyphenylene ether, polyphenylene sulfide, and styrene acrylonitrile (SAN), polyamides such as nylon 6, nylon 6/6, nylon 6/66, nylon 6/9, nylon 6/10, nylon 6/12
  • Those with low to medium melt temperatures include fluorocarbons such as polychlorotriethylene (CTFE), poly[ethylene-co- chlorotrifluoroethylene] (ECTFE) copolymer ethylene tetrafluoroethylene (ETFE), copolymer tetrafluoroethylene and hexafluoropropylene (FEP), perfluoroalkane (PFA) and poly[vinylidene fluoride] (PVDF).
  • CFE polychlorotriethylene
  • ECTFE poly[ethylene-co- chlorotrifluoroethylene]
  • ETFE copolymer ethylene tetrafluoroethylene
  • FEP copolymer tetrafluoroethylene and hexafluoropropylene
  • PFA perfluoroalkane
  • PVDF poly[vinylidene fluoride]
  • a matrix of polymer includes at least 20 percent by weight of one or more polymers.
  • a matrix can include greater than or equal to 30, 40, 50, 60, 70, 80, or 90 percent by weight of polymer(s); and/or less than or equal to 90, 80, 70, 60, 50, 40, or 30 percent by weight of polymer(s).
  • Fibers 26 are generally elongated structures having a small circumference or width in proportion to a length or height. Fibers 26 can have a variety of configurations or shapes. Fibers 26 can have a cross section that is substantially circular or substantially non-circular, such as oval, or regularly or irregularly polygonal having 3, 4, 5, 6, 7, or 8 or more sides.
  • the outer surface of fibers 26 can be relatively smooth, e.g., cylindrical or rod-like, or faceted. Fibers 26 can have a surface that is rough and irregular. Fibers 26 can have uniform or non-uniform thickness, e.g., the fibers can taper along their lengths. Mixtures of fibers having two or more different configurations or shapes can be used.
  • a fiber can extend generally linearly or crookedly. Examples of a fiber include a thread, a filament, and a whisker.
  • Fibers 26 can have a length of about 0.01 mm to about 60 mm. In some embodiments, fibers 26 can have a length greater than or equal to about 1, 10, 20, 30, 40, or 50 mm; and/or less than or equal to about 60, 50, 40, 30, 20, 10, or 1 mm. The lengths of fibers 26 may be uniform or relatively random. Fiber 26 can be a width of about 0.001 to 1 mm. Fibers 26 can have a width greater than or equal to about 0.01, 0.1, 0.5 mm; and/or less than or equal to about 1, 0.5, 0.1, or 0.01 mm. The width can be uniform or relatively random.
  • fibers 26 have length to width aspect ratios from about
  • the length to width aspect ratios can be greater than or equal to about 100:1, 500:1, 1000:1. 2500:1, or 5000:1; and/or less than or equal to about 5000:1, 2500:1, 1000:1, 500:1, or 100:1.
  • the lengths and widths are average lengths and average widths, respectively. Mixtures of fibers having two or more different aspect ratios and/or dimensions can be used.
  • Fibers 26 can be formed of any material that is stiffer and/or stronger, e.g., in the long axis, than the polymer(s) in the matrix of an endoprosthesis.
  • the fiber material can be natural or synthetic.
  • the fiber material can include carbon, ceramics (e.g., oxides, carbides, or nitrides), a metal, an alloy, bone, polysaccharides (e.g., chitosan), cellulose-based fibers, glass fibers (e.g., fiberglass), and/or sutures.
  • the fiber material can include one or more of the polymers described above, e.g., those polymers that have greater stiffness than the stiffness of a selected matrix polymer.
  • the fiber material can be radiopaque or magnetopaque (i.e., visible by magnetic resonance imaging (MRI)).
  • the fiber material can have low magnetic susceptibility to reduce MRI artifacts.
  • Suitable materials for radiopacity include, for example, gold, platinum, iridium, cobalt, titanium, tungsten, tantalum, stainless steel, Nitinol, and metal alloys containing a sufficient percentage of heavy elements.
  • Suitable materials with low magnetic susceptibility include, for example, non-ferrous metal-alloys containing paramagnetic or diamagnetic elements (e.g., gold, platinum, copper, iridium, titanium, and tantalum).
  • Suitable materials with relatively high magnetic susceptibility include iron, nickel, and cobalt. Mixtures of fibers having two or more different compositions can be used.
  • the concentration and orientation of the fibers are selected to provide the endoprosthesis with mechanical properties that match well with the mechanical properties of a body vessel while allowing the endoprosthesis to maintain the vessel open.
  • a tubular member and/or a layer that makes up a tubular member can have at least about five percent of fibers by weight.
  • the tubular member and/or layer include greater than or equal to about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, or 80 weight percent of fibers, and/or less than or equal to about 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 15, or 10 weight percent of fibers.
  • Multilayer endoprostheses can include layers having the same concentration or different concentrations of fibers.
  • the endoprostheses formed by the methods described herein have an elastic modulus along an axis substantially parallel to the reinforcement of about 700,000 psi to about 30,000,000 psi. In other embodiments, the endoprostheses have a modulus of about 1,000,000 psi to about 10,000,000 psi. Yield strength in the direction of reinforcement can be equal to or greater than about 15,000 psi. In embodiments, the endoprostheses can be radially expanded from about 2 mm (O.D.) to about 4 mm (O.D.) without substantial fracture.
  • the endoprostheses can be of any desired shape and size (e.g., coronary stents, aortic stents, peripheral stents, gastrointestinal stents, urology stents and neurology stents).
  • a coronary stent can have an expanded diameter of from about 2 millimeters to about 6 millimeters.
  • a peripheral stent can have an expanded diameter of from about 5 millimeters to about 24 millimeters.
  • a gastrointestinal and/or urology stent can have an expanded diameter of from about 6 millimeters to about 30 millimeters.
  • a neurology stent can have an expanded diameter of from about 1 millimeter to about 12 millimeters.
  • the endoprostheses can be balloon-expandable, self-expandable, or a combination of both (e.g., U.S. Patent No. 5,366,504).
  • the endoprosthesis can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene.
  • PTFE polytetrafluoroethylene
  • the endoprosthesis can include a releasable therapeutic agent or a pharmaceutically active compound, such as described in U.S. Patent No. 5,674,242, and commonly-assigned U.S.S.N. 09/895,415, filed July 2, 2001.
  • the therapeutic agents or pharmaceutically active compounds can include, for example, anti-thrombogenic agents, antioxidants, anti-inflammatory agents, anesthetic agents, anti-coagulants, and antibiotics.
  • the endoprosthesis can be used, e.g., delivered and expanded, according to conventional methods.
  • Suitable catheter systems are described in, for example, Wang U.S. 5,195,969, and Hamlin U.S. 5,270,086.
  • Suitable stents and stent delivery are also exemplified by the NIR on Ranger® system, available from Boston Scientific Scimed, Maple Grove, MN.
  • the fibers are relatively long and continuous.
  • the fibers can continuously extend the entire circumference of a tubular member or an endoprosthesis.
  • an endoprosthesis 50 includes a polymeric strip 52 that is spaced and helically wound about longitudinal axis F of the endoprosthesis.
  • Strip 52 includes fibers 26 that are oriented, e.g., parallel to or perpendicular to the length of the strip, to provide endoprosthesis 50 with radial and/or hoop strength.
  • Strip 52 can be formed according to methods described above, e.g., for sheet 28 or 46.
  • strip 52 is wound continuously around and attached to a tubular member 54, e.g., an extruded polymer tube.
  • Strip 52 can be attached, for example, by heat bonding or by using an adhesive.
  • Tubular member 54 which can be made of one or more layers, can be made of a polymer similar to that in polymeric strip 52 or a different polymer.
  • the angle at which strip 52 is wound is selected to provide a desired final orientation of the strip, allowing for any changes in orientation during expansion, if desired.
  • endoprosthesis 50 is formed, e.g., by laser cutting.
  • one or more additional polymeric layers can be formed over strip 52.
  • the additional layer(s) can be strips wound around strip 52, a tubular member slid over strip 52, and/or a casted or molded member formed over strip 52.
  • the additional layer(s) and/or tubular member 54 may include oriented fibers, e.g., as in endoprosthesis 22 and/or 42.
  • Multiple strips 52 can be used. For example, multiple strips 52 can overlap each other and/or be staggered relative to each other.
  • the strips can be wound as multiple, unconnected bands around tubular member 54.
  • the strips can have fibers that are oriented in the same or different manner.
  • no tubular member 54 is used, e.g., strip 52 can be wrapped around a mandrel, and additional layer(s) can be formed over the strip.
  • Strips 52 can be formed of a non-polymeric material.
  • a polymeric tubular member 60 includes a strip 62 in the form of a ribbon wound around the tubular member.
  • a polymeric strip (with or without fibers) can be wound to fill in gaps between strip 62.
  • Strip 62 can be closely wound, e.g., such that the windings are not spaced from each other.
  • Strip 62 can be made of a metal or an alloy, as described above.
  • Strip 62 can be radiopaque or magnetopaque. In other embodiments, strip 62 can be a filament, a wire, or a cable.
  • Tubular member 64 can be generally the same as tubular member 54, described above.
  • Tubular member 60 can be made into an endoprosthesis by the method shown in Fig. 8.
  • strip 62 can be pre-formed, e.g., pre-wound, and placed into a mold, and a polymer or a mixture of polymers can be introduced into the mold to encapsulate the strip.
  • Combinations of methods of making an endoprosthesis can be used. For example, spin casting and magnetic orientation of fibers can be combined to form an endoprosthesis.
  • Fig. 10 shows a tube mold 70 having a tubular cavity 72. Mold 70 is configured to be rotatable around its longitudinal axis G. A coil 74, formed of a pre- wound electrically conducting wire, is wrapped around mold 70.
  • a second coil is wrapped adjacent to the inner surface 76 of cavity 72.
  • Coil 74 is capable of carrying a current such that a magnetic flux is induced wherein the flux lines extend within the windings of the coil and circumferentially around mold 70 (arrows H).
  • Mold 70 can be made or a diamagnetic material or a paramagnetic material so that the mold does not become magnetic and attract fibers. Mold 70 can be made of, for example, copper, tantalum, or titanium.
  • a mixture of polymer(s) and fibers e.g., ferromagnetic or paramagnetic fibers
  • a current is passed through coil 74 to induce flux lines extending circumferentially about mold 70.
  • the fibers can circumferentially orient with the induced magnetic field.
  • Mold 70 can be rotated about axis G to enhance uniformity and orientation. In embodiments, no magnetic field is created, but mold 70 is rotated to radially orient the fibers, e.g., asymmetrical fibers, as in spin casting described above.

Abstract

Medical devices, for example, implantable devices such as endoprostheses, include a composite material having a polymer.

Description

MEDICAL DEVICES AND METHODS OF MAKING THE SAME
TECHNICAL FIELD
[0001] The invention relates to medical devices, such as, for example, endoprostheses, and methods of making the devices.
BACKGROUND
[0002] The body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprosthesis include stents and covered stents, sometimes called "stent-grafts".
[0003] Endoprostheses can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
[0004] The expansion mechanism may include forcing the endoprosthesis to expand radially. For example, the expansion mechanism can include the catheter carrying a balloon, which carries a balloon expandable endoprosthesis. The balloon can be inflated to deform and to fix the expanded endoprosthesis at a predetermined position in contact with the lumen wall. The balloon can then be deflated, and the catheter withdrawn.
[0005] In another technique, a self-expandable endoprosthesis is formed of an elastic material that can be reversibly compacted and expanded, e.g., elastically or through a material phase transition. During introduction into the body, the endoprosthesis is restrained in a compacted condition on a catheter. Upon reaching the desired implantation site, the restraint is removed, for example, by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force.
[0006] To support a passageway open, endoprostheses can be made of relatively stiff and strong materials, such as stainless steel or Nitinol (a nickel-titanium alloy), that can resist compression and/or dislocation of the endoprostheses. The physical or mechanical properties of the endoprosthesis materials, however, sometimes do not closely match those properties of the body vessel, which is relatively compliant and resilient. The mismatch in properties, and the presence of the endoprosthesis (a foreign object) in the body, can cause the vessel to become inflamed and/or re-occluded.
SUMMARY
[0007] The invention relates to medical devices, such as, for example, endoprostheses, and methods of making the devices. In one aspect, the invention features endoprostheses that have physical and mechanical properties (e.g., resiliency or compliancy) similar to those of a body vessel, thereby reducing the occurrence of inflammation and/or re-occlusion. At the same time, the endoprostheses have good radial and/or hoop strengths, e.g., to maintain the body vessel open and to resist dislodgement after implantation. In some embodiments, the endoprostheses are formed of a composite including a polymer.
[0008] In one aspect, the invention features an endoprosthesis having a tubular member including a polymer matrix and a plurality of fibers in the matrix. The fibers have a stiffness greater than the stiffness of the polymer and are substantially oriented in a predetermined direction. In embodiments, the fibers can be oriented substantially circumferentially, longitudinally, and/or radially relative to a longitudinal axis of the tubular member.
[0009] Embodiments may include one or more of the following features. The fibers include a metal (such as gold, tantalum, platinum, or tungsten) and/or a polymer. The fibers are dispersed throughout substantially the entire matrix. The fibers are formed on preselected portions of the tubular member. The fibers extend helically around the tubular member. The fibers are formed in a configuration that enhances the radial, hoop, and/or longitudinal strength of the tubular member. The fibers have a first end that is larger than a second end. The fibers are visible by magnetic resonance imaging. The endoprosthesis further includes a magnetopaque material different than the fibers in the matrix.
[0010] The tubular member can be formed of a plurality of polymeric layers. The plurality of polymeric layers can include a layer having fibers oriented substantially longitudinally relative to the tubular member, and a layer having fibers oriented substantially radially or circumferentially relative to the tubular member.
[0011] The endoprosthesis can further include a drug-releasing layer on the tubular member. The matrix can include a drug.
[0012] The endoprosthesis can be in the form of a balloon-expandable stent.
[0013] In another aspect, the invention features an endoprosthesis including a tubular member having a polymer, and a first member extending helically around the tubular member. The first member has a stiffness greater than stiffness of the polymer.
[0014] Embodiments may include one or more of the following features. The first member includes a metal and/or a polymer. The tubular member includes a plurality of fibers in the polymer that has a stiffness greater than the stiffness of the polymer and is substantially oriented in a predetermined direction. The polymer encapsulates the first member.
[0015] In another aspect, the invention features a endoprosthesis having a tubular member having a first layer including a first polymer, and a second layer including a second polymer and a plurality of fibers in the second polymer. The fibers have a stiffness greater than the stiffness of the polymer and are oriented in a predetermined direction.
[0016] Embodiments may include one or more of the following features. The first layer further includes a plurality of fibers oriented in a predetermined direction. The pluralities of fibers in the first and second layers are substantially the same. The pluralities of fibers in the first and second layers are oriented in different directions. The pluralities of fibers in the first and second layers are oriented in the same direction. The first and second polymers are the same polymer.
[0017] Embodiments may further include one or more of the following advantages.
The medical devices are relatively compatible with magnetic resonance imaging (MRI). The devices can be resected, e.g., after implantation. The devices are relatively resistant to fracture.
[0018] Other aspects, features, and advantages of the invention will be apparent from the description of the preferred embodiments thereof and from the claims. DESCRIPTION OF DRAWINGS
[0019] Fig. 1 is an illustration an embodiment of an endoprosthesis;
[0020] Fig. 2 is an illustration an embodiment of an endoprosthesis;
[0021] Fig. 3 is an illustration an embodiment of an endoprosthesis;
[0022] Fig. 4 is an illustration an embodiment of an endoprosthesis;
[0023] Fig. 5 is an illustration an embodiment of a method of making the endoprosthesis of Fig. 1; [0024] Fig. 6 is an illustration an embodiment of a method of making an endoprosthesis; [0025] Fig. 7 is an illustration an embodiment of a method of making an endoprosthesis; [0026] Fig. 8 is an illustration an embodiment of a method of making an endoprosthesis; [0027] Fig. 9 is an illustration of an embodiment of a tubular member; and
[0028] Fig. 10 is an illustration of an embodiment of a device for making an endoprosthesis.
DETAILED DESCRIPTION
[0029] Fig. 1 shows an endoprosthesis 22, here, a slotted tube stent, including a tubular member 23 formed of a matrix of polymer 24 and a plurality of fibers 26 preferentially oriented in a predetermined direction within the matrix. The polymer provides endoprosthesis 22 with mechanical properties, such as resiliency and compliancy, that match well with the mechanical properties of a body vessel. As a result, the occurrence of inflammation and/or re-occlusion can be reduced. Fibers 26 are formed of a material, such as a metal, that is stiffer than the polymer and can reinforce matrix 24. As shown in Fig. 1, fibers 26 are oriented circumferentially (arrow A) around tubular member 23. As a result, fibers 26 can enhance the hoop strength of tubular member 23, which helps endoprosthesis 22 to resist compression, thereby maintaining the body vessel open.
[0030] Other orientations of fibers 26 are possible. In embodiments, fibers 26 are oriented in one or more directions to strengthen matrix 24 (e.g., relative to the matrix with the fibers) along the loading axes of endoprosthesis 22, such as in the radial and/or hoop direction. For example, referring to Fig. 2, an endoprosthesis 42 includes fibers 26 that are oriented radially (arrow B) to enhance the radial strength of the endoprosthesis. Fibers 26 can be oriented longitudinally, i.e., parallel to the length of the endoprosthesis, which can enhance axial stiffness.
[0031] In some embodiments, an endoprosthesis is formed of multiple layers, e.g., greater than or equal to two, three, four, five or six layers. The layers can be the same or different relative to each other, e.g., with respect to the type and/or composition of polymer(s) and/or fiber, the amount of fiber in each layer, and/or the orientation of the fibers. For example, a multilayer endoprosthesis may include one or more layers having fibers that are oriented radially, one or more layers having fibers that are oriented circumferentially, and/or one or more layers having no fibers, which can enhance the compliancy and resiliency of the endoprosthesis. The layers can have the same or different thickness. Any combination or sequencing of layering is possible, depending on the desired mechanical and physical properties. For example, to provide an endoprosthesis with both good hoop strength and radial strength, an endoprosthesis may include layers of radially oriented fibers alternating with layers of circumferentially oriented fibers (Fig. 3). The layers can be grouped together, e.g., the layers with radially oriented fibers can be the inner layers and the layers with circumferentially oriented fibers can be the outer layers, or vice versa (Fig. 4).
[0032] Referring to Fig. 5, a method 20 of making endoprosthesis 22 having circumferentially oriented fibers 26 generally includes forming a polymeric sheet 28 having the fibers oriented parallel to longitudinal axis C of the sheet. Methods of making sheet 28 include, for example, forming a mixture of the polymer of matrix 24 and fibers 26, and pultruding the mixture. Pultrusion is described in, for example, C. A. Harper, Handbook of Plastics and Elastomers, McGraw-Hill Book Co., New York 1975, 5-88 to 5-89, hereby incorporated by reference. In other embodiments, sheet 28 can be formed by positioning, e.g., laying flat, fibers 26 in a desired orientation in a mold. The matrix polymer can then be introduced into the mold in a solid or liquid state. Heat and/or pressure are then applied to allow the polymer to encapsulate the fibers.
[0033] Sheet 28 can then be wound, e.g., circumferentially, around a mandrel, and opposing edges 30 of the sheet can be joined together, e.g., by welding or by an adhesive, to form tubular member 23. Tubular member 23 can be drawn and/or cut to size, as needed, and portions of the tubular member are removed to form openings 32 of endoprosthesis 22. Endoprosthesis 22 can be cut and/or formed by laser cutting, as described in U.S. Patent No. 5,780,807, hereby incorporated by reference in its entirety. In other embodiments, a plurality of sheets 28 can be laminated together, e.g., using an adhesive or by heat bonding, and wrapped around a mandrel to form tubular member 23 and endoprosthesis 22.
[0034] In some cases, the orientation of fibers 26 may change from their initial orientation when the endoprosthesis is expanded during use. Referring to Fig. 6, to compensate for a change in the orientation of fibers 26, an endoprosthesis 34 can be formed in which strips of sheet 28 are wound, e.g., helically, at a predetermined initial angle around the mandrel. When endoprosthesis 34 is radially expanded during use, strips 28 and fibers 26 can orient to a desired final orientation, e.g., substantially circumferentially and perpendicular to longitudinal axis D of endoprosthesis 34. The initial winding angle of strips 28 can be, for example, from about 5 to about 85 degrees relative to axis D. Adjacent edges of strips 28 can be joined together, for example, by gluing the edges and/or selectively melting and re-solidifying the edges.
[0035] Referring to Figs. 2 and 7, a method 40 of making endoprosthesis 42 having radially oriented fibers 26 includes forming a polymeric sheet 46 in which the fibers are oriented perpendicular to longitudinal axis E of the sheet. After sheet 46 with oriented fibers 44 is formed, the sheet can be formed into endoprosthesis 42 as described above. For example, sheet 46 or strips of the sheet can be wound, e.g., circumferentially or helically, around a mandrel, and edges of the sheet can be bonded together to form a tubular member. The tubular member can then be formed into endoprosthesis 42, e.g., by laser cutting. As shown in Fig. 7, multiple sheets 46 are laminated together, and the multilayer laminate can be wound around the mandrel and formed into endoprosthesis 42.
[0036] Numerous methods can be used to orient fibers 26 perpendicular to longitudinal axis E of sheet 46. For example, fibers 26 can be manually pressed into an unsolidified sheet of polymer, and/or the fibers can be sprayed into an unsolidified sheet of polymer using a spray nozzle with an appropriate size and geometry. Fibers 26 can be formed having a first end heavier than a second end, e.g., by forming a stub on the first end or by tapering the size of the fiber. The fibers are then placed into an unsolidified sheet of polymer. The heavier ends of the fibers tend to align the fibers perpendicular to longitudinal axis E of sheet 46. In other embodiments, asymmetrical fibers, e.g., those having one end heavier than another end, can be mixed with the matrix polymer and spin casted (e.g., about the longitudinal axis) in a mold to form a tubular member. The centrifugal force generated during spin casting can orient the fibers in the polymer, e.g., the fibers can orient radially, with the heavier ends outward of the lighter ends.
[0037] In some embodiments, magnetic fibers 26, e.g., ferromagnetic or paramagnetic fibers, such as 300 series stainless steel, can be oriented by placing an unsolidified sheet having the fibers in a magnetic field such that the magnetic flux lines are perpendicular to longitudinal axis E of the sheet. To compensate for changes in the orientation of fibers 26 during expansion of endoprosthesis 42, the magnetic flux lines may be non-perpendicular to longitudinal axis E to orient fibers 26 in a desired initial orientation.
[0038] A multilayer endoprosthesis in which the layers are different can be made by winding a sheet of polymer (with or without fibers) around a preformed tubular member. For example, to form the endoprosthesis shown in Fig. 3, the innermost layer can be formed by method 20 to form tubular member 23. Sheet 46 can then be wrapped and secured around tubular member 23. A second sheet 28 can then be wound around and secured to sheet 46. In other embodiments, close fitting tubular members (with or without fibers) having an adhesive material between the tubular members can be co-drawn to form a multilayer endoprosthesis.
[0039] The polymer used in the endoprostheses described herein can be any polymer that is biocompatible. For example, for vascular stents or stent-grafts, the polymer preferably has acceptable vascular compatibility, e.g., relatively low thrombogenecity and low cytotoxicity. For non- vascular stents or stent-grafts, the polymer is preferably stable in various bodily fluids. The polymer can be biodegradable, for example, if the polymer is used for temporary endoprostheses.
[0040] In some embodiments, the polymer can be relatively stiff or hard, e.g., having a hardness of more than about 50 Shore D, such as 72 Shore D or more. In multilayer endoprostheses, the layers may or may not include the same polymer. The difference in hardness of adjacently bonded layers can be about 40 Shore D or less, such as 20 Shore D or less, which can enhance compatibility between the layers, and/or reduce delamination at the interface. Hardness may be measured according to ASTM D2240. [0041] In embodiments, the polymer can have an elastic modulus of about 10,000-
2,000,000 psi. The elastic modulus can be equal to or greater than about 100,000, 500,000, 1,000,000, or 1,500, 000 psi; and/or equal to or less than 2,000,000, 1,500,000, 1,000,000, 500,000, or 100,000 psi. Alternatively or in addition, the polymer can have an elongation to fracture equal to or greater than about 10%, e.g., equal to or greater than about 20%, 30%, 40%, or 50%. Alternatively or in addition, the polymer can have a yield strength equal to or greater than about 10,000 psi, e.g., equal to or greater than about 25,000 psi or 50,000 psi.
[0042] The polymer may be of a substantially pure polymer or may be blends of different polymers. The polymer can be made of block copolymers including common block moieties, which can enhance compatibility, while maintaining defect retardation. For example, the block moieties may be amide segments and tetramethylene glycol segments. An example is the PEBAX® family of polymers, which can be used pure or as blends (available from Atofina, Philadelphia, PA). For example, PEBAX® 5533 (55 Shore D) can be blended with PEBAX® 2533 (25 Shore D) in a weight ratio of about 4 to 1 to provide a soft polymer of about 50 Shore D. Another combination of polymers is polybutylene terephthalate (PBT) such as CELANEX® (over 80 Shore D, from Ticona, Summit, NJ) and polyester/ether block copolymer available as ARNITEL® (55 Shore D, from DSM, Erionspilla, IN). Another combination of polymers is PBT and one or more PBT thermoplastic elastomers, such as RITEFLEX® (55 Shore D from Ticona in Summit, NJ) and HYTREL® (55 Shore D from E. I. Dupont de Nemours, Wilmington, DE) for example. Still another combination of polymers is polyethylene terephthalate (PET) and a thermoplastic elastomer, such as a PBT thermoplastic elastomer (e.g., ARNITEL®, HYTREL®, or RITEFLEX®).
[0043] In certain embodiments, one or more layers can contain one or more nylons.
For example, a combination of polymers is a nylon and a PEBAX®-type material, such as PEBAX®, GRILON®, GRILAMID® (EMS) and/or VESTAMID® (Creanova). Examples of nylons include aliphatic nylons, such as Nylon 11 (Elf Atochem), Nylon 6 (Allied Signal), Nylon 6/10 (BASF), Nylon 6/12 (Ashley Polymers) and Nylon 12. Additional examples of nylons include aromatic nylons, such as GRIVORY® (EMS) and Nylon MXD-6. Other nylons and/or combinations of nylons can be used.
[0044] In some embodiments, one or more layers can contain a liquid crystal polymer
(LCP) (e.g., a composite material having the LCP incorporated therein). Examples of LCPs include polyester(s), polyamide(s) and/or their copolymers, such as NECTRA® A (Ticona), NECTRA® B (Ticona) and VECTRA® LKX (Ticona) (e.g., NECTRA® LKX 1111 (Ticona)). Other LCPs and/or combinations of LCPs can be used.
[0045] The LCP can be incorporated into one or more polymers, such as, for example, a PEBAX®-type material, a nylon, a thermoplastic polyester and/or thermoplastic elastomer versions thereof. In certain embodiments, the liquid crystal polymer can be incorporated into one or more of the polymer layers to form a hard layer of material (e.g., a layer of material with more than about 60 Shore D hardness, such as more than about 65 Shore D hardness). In one combination, an LCP is incorporated into a layer containing one or more PEBAX®-type materials, such as PEBAX®, GRILOΝ®, GRILAMID®, and/or NESTAMID®. In certain embodiments, an LCP-containing composition can be relatively stiff in the direction of melt flow. Without wishing to be bound by theory, it is believed that this may result because LCP crystals (e.g., fibers) form or align in the melt flow direction as the polymer composite cools from a liquid state to a solid state. It is believed that the LCP fibers can reinforce the other polymer(s) contained in the layer (e.g., matrix polymer(s)).
[0046] The amount of LCP contained in the tube or balloon can vary depending upon its intended use. In some embodiments, as the percentage of LCP in a composite material is decreased, the individual layer thickness and the overall thickness of one or more layers of an LCP-containing composite material can be increased.
[0047] The LCP content of a tube can be at least about 0.1 weight percent, such as from about 0.1 weight percent to about 20 weight percent (e.g., from about 0.5 weight percent to about 10 weight percent, from about one to about five weight percent). Within a given layer, the LCP content can be at least about 0.1 weight percent (e.g., from about one weight percent to about 50 weight percent, from about five weight percent to about 20 weight percent, from about five weight percent to about 15 weight percent).
[0048] In certain multilayer endoprostheses, an adhesion enhancing material can be incorporated into one or more material layers. An adhesion enhancing material can be used, for example, to enhance the adhesion between adjacent layers. Examples of adhesion enhancing materials include epoxy or anhydride modified polyolefms, such as LOTADER® (Elf Atochem) and KODAR® PETG (Eastman Kodak). An adhesion enhancing material can be added to a material (e.g., a composition containing one or more polymers), e.g., prior to molding or pultrusion. For example, in embodiments in which alternate layers include PET and PBT, PETG can be added to the PET.
[0049] The amount of adhesion enhancing material can vary depending upon the intended use. In some embodiments, a sufficient amount of adhesion enhancing material(s) are included in the material so that the adhesion enhancing material(s) makes up at least about 0.5 percent of the resulting mixture that forms the layer (e.g., at least about one percent, at least about five percent, at least about 10 percent) and/or at most about 20 percent of the resulting mixture that forms the layer (e.g., at most about 15 percent, at most about 12 percent, at most about 10 percent).
[0050] In some embodiments, a compatibilizing material can be incorporated into one or more material layers. The compatibilizing material can be designed, for example, to modify one or more phase boundaries of the LCP(s) and one or more of the other polymer(s) (e.g., thermoplastic polymer(s)) and/or to enhance adhesion between the LCPs and one or more of the other polymer(s). The compatibilizing material can be a copolymer, such as a block copolymer, including moieties of at least two different chemical structures, respectively providing compatibility with an LCP and one or more other polymers in the mixture. The compatibilizing material can be a reactive polymer that reacts with the LCP and/or one or more other polymers in the mixture. The compatibilizing material can be a catalyst that promotes a reaction between the LCP and one or more other polymers in the mixture. Other compatibilizing materials can be used. Combinations of compatibilizing materials can be used.
[0051] Examples of compatibilizing materials include copolyester elastomers, ethylene unsaturated ester copolymers, such as ethylene-maleic anhydride copolymers, copolymers of ethylene and a carboxylic acid or acid derivative, such as ethylene- methyl acrylate copolymers, polyolefms or ethylene-unsaturated ester copolymers grafted with functional monomers, such as ethylene-methyl acrylate copolymers, copolymers of ethylene and a carboxylic acid or acid derivative, such as ethylene- methyl acrylate maleic anhydride terpolymers, terpolymers of ethylene, unsaturated ester and a carboxylic acid or acid derivative, such as ethylene-methyl acrylate- methacrylic acid terpolymers, maleic acid grafted styrene-ethylene-butadiene-styrene block copolymers, and acrylic acid elastomers, such as acrylic rubbers. Similar polymers containing epoxy functional groups, for instance derived from glycidyl methylacrylate (e.g., alkyl(meth)acrylate-ethylene-glycidyl (meth)acrylate polymers) can be used. Ionomeric copolymers can be used. PETG can be used. Examples of compatibilizing materials include HYTREL® HTR-6108, POLYBOND® 3009 (BP Chemicals), SP 2205 (Chevron), DS 1328/60 (Chevron), LOTADER® 2400, ESCOR® ATX-320, ESCOR® ATX-325, NAMAC® Gl and LOTADER® AX8660. In certain embodiments, a compatibilizing material (e.g., PETG) can be mixed with one or more polymers (e.g., an LCP-containing material), e.g., prior to extrusion.
[0052] There are many ways in which LCPs can be blended into thermoplastics. The
LCP blend can be a ternary system of LCP, thermoplastic and compatibilizing materials. Systems with multiple combinations of different LCPs, different thermoplastics and different compatibilizing materials are contemplated.
[0053] The compatibilized blend can be a blend of polyazomethine LCP, a thermoplastic polymer such as a polyamide, and a compatibilizing material such as a caprolactum having at least one functional group capable of showing compatibility and/or reactivity to the LCP and/or the thermoplastic polymer. Such blends are described, for example, in U.S. Patent No. 5,565,530, which is hereby incorporated by reference.
[0054] One polymer blend product which can be used include PET, a wholly aromatic
LCP copolyester and an ethylene-methyl acrylate-acrylic acid terpolymer compatibilizing material, such as, for example, ESCOR® ATX320, ESCOR® ATX325, or ESCOR® XV-11.04. Another polymer blend product includes PET, a wholly aromatic LCP copolyester and an ethylene-maleic anhydride copolymer compatibilizing material, such as POLYBOND® 3009. Another polymer blend product includes PET, a wholly aromatic LCP copolyester and an ethylene-methyl acrylate copolymer grated with maleic anhydride compatibilizing material, such as DS 1328/60, or a copolyester elastomer, such as HYTREL® HTR 6108.
[0055] Polymer blend products including PET, LCP and at least two compatibilizing materials can be used. For example, DS 1328/60 and POLYBOND® 3009 can be used with the LCP NECTRA®. As an additional example, when the LCP is VECTRA®, the compatibilizing materials can be POLYBOND® 3009 and at least one additional compatibilizing material selected from ESCOR® ATX-320, ESCOR® ATX-325, DS 1328160, ESCOR® XV-11.04 and HYTREL® HTR-6108. [0056] In certain embodiments, consideration is given to the properties of the LCP and the other polymer(s) (e.g., PET), as well as the desired properties of the resulting blend, when selecting the compatibilizing material(s).
[0057] In some embodiments containing an LCP, a thermoplastic polymer and compatibilizing material(s), the blend product includes from about 0.1 weight percent to about 10 weight percent (e.g., from about 0.5 weight percent to about 2 percent) LCP, from about 40 weight percent to about 99 weight percent (e.g., from about 85 weight percent to about 99 weight percent) thermoplastic polymer, and from about 0.1 weight percent to about 30 weight percent (e.g., from about one weight percent to about 10 weight percent) compatibilizing material(s).
[0058] While certain polymers and polymer combinations are discussed above, other polymers and polymer combinations can also be used. Other polymers include, for example, elastomers such as thermoplastic elastomers and engineering thermoplastic elastomers, such as polybutylene terephthalate-polyethene glycol block copolymers, which are available, for example, as HYTREL®. These are discussed in Hamilton U.S. 5,797,877, the entire content of which is incorporated herein by reference. Other polymers include polyurethenes, polytetrafluoroethylene (PTFE), polylactic acid (PLA), styrene-isobutylene-styrene (SIBS), polypropylene, and polyglycolide. Other polymers include copolymers such as ABS (acrylonitrile-butadiene-styrene), ABS/nylon, ABSApolyvinyl chloride (PVC), ABS/polycarbonate, acrylonitrile copolymer, polyacrylamide, polyacrylate and polyacrylsulfone, polyesters such as polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyethylene naphthalate (PEN), liquid crystal polymer (LCP), polyester/polycaprolactone and polyester/polyadipate; and high melt temperature polyethers including polyetheretherketone (PEEK), polyethersulfone (PES), polyetherimide (PEI) and polyetherketone (PEK), polymenthylpentene, polyphenylene ether, polyphenylene sulfide, and styrene acrylonitrile (SAN), polyamides such as nylon 6, nylon 6/6, nylon 6/66, nylon 6/9, nylon 6/10, nylon 6/12, nylon 11, nylon 12, ethylene, propylene ethylene vinylacetate and ethylene vinyl alcohol (EVA), various ionomers, polyethylene type I-IV, polyolefms, polyurethane, polyvinyl chloride, and polysiloxanes (silicones). Those with low to medium melt temperatures include fluorocarbons such as polychlorotriethylene (CTFE), poly[ethylene-co- chlorotrifluoroethylene] (ECTFE) copolymer ethylene tetrafluoroethylene (ETFE), copolymer tetrafluoroethylene and hexafluoropropylene (FEP), perfluoroalkane (PFA) and poly[vinylidene fluoride] (PVDF).
[0059] In some embodiments, a matrix of polymer includes at least 20 percent by weight of one or more polymers. For example, a matrix can include greater than or equal to 30, 40, 50, 60, 70, 80, or 90 percent by weight of polymer(s); and/or less than or equal to 90, 80, 70, 60, 50, 40, or 30 percent by weight of polymer(s).
[0060] Fibers 26 are generally elongated structures having a small circumference or width in proportion to a length or height. Fibers 26 can have a variety of configurations or shapes. Fibers 26 can have a cross section that is substantially circular or substantially non-circular, such as oval, or regularly or irregularly polygonal having 3, 4, 5, 6, 7, or 8 or more sides. The outer surface of fibers 26 can be relatively smooth, e.g., cylindrical or rod-like, or faceted. Fibers 26 can have a surface that is rough and irregular. Fibers 26 can have uniform or non-uniform thickness, e.g., the fibers can taper along their lengths. Mixtures of fibers having two or more different configurations or shapes can be used. A fiber can extend generally linearly or crookedly. Examples of a fiber include a thread, a filament, and a whisker.
[0061] Fibers 26 can have a length of about 0.01 mm to about 60 mm. In some embodiments, fibers 26 can have a length greater than or equal to about 1, 10, 20, 30, 40, or 50 mm; and/or less than or equal to about 60, 50, 40, 30, 20, 10, or 1 mm. The lengths of fibers 26 may be uniform or relatively random. Fiber 26 can be a width of about 0.001 to 1 mm. Fibers 26 can have a width greater than or equal to about 0.01, 0.1, 0.5 mm; and/or less than or equal to about 1, 0.5, 0.1, or 0.01 mm. The width can be uniform or relatively random.
[0062] In some embodiments, fibers 26 have length to width aspect ratios from about
10:1 to about 6000:1, although higher aspect ratios are possible. In some embodiments, the length to width aspect ratios can be greater than or equal to about 100:1, 500:1, 1000:1. 2500:1, or 5000:1; and/or less than or equal to about 5000:1, 2500:1, 1000:1, 500:1, or 100:1. The lengths and widths are average lengths and average widths, respectively. Mixtures of fibers having two or more different aspect ratios and/or dimensions can be used.
[0063] Fibers 26 can be formed of any material that is stiffer and/or stronger, e.g., in the long axis, than the polymer(s) in the matrix of an endoprosthesis. The fiber material can be natural or synthetic. For example, the fiber material can include carbon, ceramics (e.g., oxides, carbides, or nitrides), a metal, an alloy, bone, polysaccharides (e.g., chitosan), cellulose-based fibers, glass fibers (e.g., fiberglass), and/or sutures. The fiber material can include one or more of the polymers described above, e.g., those polymers that have greater stiffness than the stiffness of a selected matrix polymer.
[0064] The fiber material can be radiopaque or magnetopaque (i.e., visible by magnetic resonance imaging (MRI)). The fiber material can have low magnetic susceptibility to reduce MRI artifacts. Suitable materials for radiopacity include, for example, gold, platinum, iridium, cobalt, titanium, tungsten, tantalum, stainless steel, Nitinol, and metal alloys containing a sufficient percentage of heavy elements. Suitable materials with low magnetic susceptibility include, for example, non-ferrous metal-alloys containing paramagnetic or diamagnetic elements (e.g., gold, platinum, copper, iridium, titanium, and tantalum). Suitable materials with relatively high magnetic susceptibility include iron, nickel, and cobalt. Mixtures of fibers having two or more different compositions can be used.
[0065] The concentration and orientation of the fibers are selected to provide the endoprosthesis with mechanical properties that match well with the mechanical properties of a body vessel while allowing the endoprosthesis to maintain the vessel open. For example, a tubular member and/or a layer that makes up a tubular member can have at least about five percent of fibers by weight. In embodiments, the tubular member and/or layer include greater than or equal to about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, or 80 weight percent of fibers, and/or less than or equal to about 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 15, or 10 weight percent of fibers. Multilayer endoprostheses can include layers having the same concentration or different concentrations of fibers.
[0066] In some embodiments, the endoprostheses formed by the methods described herein have an elastic modulus along an axis substantially parallel to the reinforcement of about 700,000 psi to about 30,000,000 psi. In other embodiments, the endoprostheses have a modulus of about 1,000,000 psi to about 10,000,000 psi. Yield strength in the direction of reinforcement can be equal to or greater than about 15,000 psi. In embodiments, the endoprostheses can be radially expanded from about 2 mm (O.D.) to about 4 mm (O.D.) without substantial fracture. [0067] In general, the endoprostheses can be of any desired shape and size (e.g., coronary stents, aortic stents, peripheral stents, gastrointestinal stents, urology stents and neurology stents). In certain embodiments, a coronary stent can have an expanded diameter of from about 2 millimeters to about 6 millimeters. In some embodiments, a peripheral stent can have an expanded diameter of from about 5 millimeters to about 24 millimeters. In certain embodiments, a gastrointestinal and/or urology stent can have an expanded diameter of from about 6 millimeters to about 30 millimeters. In some embodiments, a neurology stent can have an expanded diameter of from about 1 millimeter to about 12 millimeters. The endoprostheses can be balloon-expandable, self-expandable, or a combination of both (e.g., U.S. Patent No. 5,366,504).
[0068] In other embodiments, the endoprosthesis can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene. The endoprosthesis can include a releasable therapeutic agent or a pharmaceutically active compound, such as described in U.S. Patent No. 5,674,242, and commonly-assigned U.S.S.N. 09/895,415, filed July 2, 2001. The therapeutic agents or pharmaceutically active compounds can include, for example, anti-thrombogenic agents, antioxidants, anti-inflammatory agents, anesthetic agents, anti-coagulants, and antibiotics.
[0069] The endoprosthesis can be used, e.g., delivered and expanded, according to conventional methods. Suitable catheter systems are described in, for example, Wang U.S. 5,195,969, and Hamlin U.S. 5,270,086. Suitable stents and stent delivery are also exemplified by the NIR on Ranger® system, available from Boston Scientific Scimed, Maple Grove, MN.
[0070] Other Embodiments
[0071] In embodiments, the fibers are relatively long and continuous. For example, the fibers can continuously extend the entire circumference of a tubular member or an endoprosthesis.
[0072] In other embodiments, the fibers may be formed on selected portions of the endoprosthesis, e.g., the fibers need not be dispersed throughout the entire endoprosthesis. Referring to Fig. 8, an endoprosthesis 50 includes a polymeric strip 52 that is spaced and helically wound about longitudinal axis F of the endoprosthesis. Strip 52 includes fibers 26 that are oriented, e.g., parallel to or perpendicular to the length of the strip, to provide endoprosthesis 50 with radial and/or hoop strength. Strip 52 can be formed according to methods described above, e.g., for sheet 28 or 46.
[0073] To form endoprosthesis 50, strip 52 is wound continuously around and attached to a tubular member 54, e.g., an extruded polymer tube. Strip 52 can be attached, for example, by heat bonding or by using an adhesive. Tubular member 54, which can be made of one or more layers, can be made of a polymer similar to that in polymeric strip 52 or a different polymer. The angle at which strip 52 is wound is selected to provide a desired final orientation of the strip, allowing for any changes in orientation during expansion, if desired. After strip 52 is attached to tubular member 54, endoprosthesis 50 is formed, e.g., by laser cutting.
[0074] Other embodiments are contemplated. In some embodiments, one or more additional polymeric layers can be formed over strip 52. The additional layer(s) can be strips wound around strip 52, a tubular member slid over strip 52, and/or a casted or molded member formed over strip 52. The additional layer(s) and/or tubular member 54 may include oriented fibers, e.g., as in endoprosthesis 22 and/or 42. Multiple strips 52 can be used. For example, multiple strips 52 can overlap each other and/or be staggered relative to each other. The strips can be wound as multiple, unconnected bands around tubular member 54. The strips can have fibers that are oriented in the same or different manner. In some cases, no tubular member 54 is used, e.g., strip 52 can be wrapped around a mandrel, and additional layer(s) can be formed over the strip.
[0075] Strips 52 can be formed of a non-polymeric material. Referring to Fig. 9, a polymeric tubular member 60 includes a strip 62 in the form of a ribbon wound around the tubular member. A polymeric strip (with or without fibers) can be wound to fill in gaps between strip 62. Strip 62 can be closely wound, e.g., such that the windings are not spaced from each other. Strip 62 can be made of a metal or an alloy, as described above. Strip 62 can be radiopaque or magnetopaque. In other embodiments, strip 62 can be a filament, a wire, or a cable. Tubular member 64 can be generally the same as tubular member 54, described above.
[0076] Tubular member 60 can be made into an endoprosthesis by the method shown in Fig. 8. Alternatively, strip 62 can be pre-formed, e.g., pre-wound, and placed into a mold, and a polymer or a mixture of polymers can be introduced into the mold to encapsulate the strip. [0077] Combinations of methods of making an endoprosthesis can be used. For example, spin casting and magnetic orientation of fibers can be combined to form an endoprosthesis. Fig. 10 shows a tube mold 70 having a tubular cavity 72. Mold 70 is configured to be rotatable around its longitudinal axis G. A coil 74, formed of a pre- wound electrically conducting wire, is wrapped around mold 70. Alternatively or in addition, a second coil is wrapped adjacent to the inner surface 76 of cavity 72. Coil 74 is capable of carrying a current such that a magnetic flux is induced wherein the flux lines extend within the windings of the coil and circumferentially around mold 70 (arrows H). Mold 70 can be made or a diamagnetic material or a paramagnetic material so that the mold does not become magnetic and attract fibers. Mold 70 can be made of, for example, copper, tantalum, or titanium.
[0078] During fabrication, a mixture of polymer(s) and fibers, e.g., ferromagnetic or paramagnetic fibers, is introduced to cavity 72. To orient the fibers circumferentially within cavity 72, a current is passed through coil 74 to induce flux lines extending circumferentially about mold 70. As a result, the fibers can circumferentially orient with the induced magnetic field. Mold 70 can be rotated about axis G to enhance uniformity and orientation. In embodiments, no magnetic field is created, but mold 70 is rotated to radially orient the fibers, e.g., asymmetrical fibers, as in spin casting described above.
[0079] The subject matter described herein can be applied to other medical devices, such as, for example, catheters, medical tubing, introducer sheaths, and guide wire tips. Examples of balloon catheters are described in, for example, U.S. 5,195,969, and U.S. 5,270,086, all hereby incorporated by reference; and are exemplified by the Ranger® system available from Boston Scientific Scimed, Maple Grove, MN. Introducer sheaths are described in U.S. 6,066,100, and guide wires are described in U.S. 6,340,441.
[0080] All publications, applications, and patents referred to herein are incorporated by reference in their entirety.
[0081] Other embodiments are within the claims.

Claims

WHAT IS CLAIMED IS:
1. An endoprosthesis, comprising: a tubular member including a polymer matrix and a plurality of fibers in the matrix, the fibers having a stiffness greater than the stiffness of the polymer and being substantially oriented in a predetermined direction.
2. The endoprosthesis of claim 1, wherein the fibers are oriented substantially circumferentially relative to a longitudinal axis of the tubular member.
3. The endoprosthesis of claim 1, wherein the fibers are oriented substantially longitudinally relative to the tubular member.
4. The endoprosthesis of claim 1, wherein the fibers are oriented substantially radially relative to the tubular member.
5. The endoprosthesis of claim 1, wherein the fibers comprise a metal.
6. The endoprosthesis of claim 1 , wherein the fibers comprise a polymer.
7. The endoprosthesis of claim 1, wherein the fibers are dispersed throughout substantially the entire matrix.
8. The endoprosthesis of claim 1, wherein the fibers are formed on preselected portions of the tubular member.
9. The endoprosthesis of claim 1, wherein the fibers extend helically around the tubular member.
10. The endoprosthesis of claim 1, wherein the fibers are formed in a configuration that enhances the radial strength of the tubular member.
11. The endoprosthesis of claim 1 , wherein the fibers are formed in a configuration that enhances the hoop strength of the tubular member.
12. The endoprosthesis of claim 1, wherein the fibers have a first end that is larger than a second end.
13. The endoprosthesis of claim 1, wherein the fibers are formed of a material selected from the group of gold, tantalum, platinum, and tungsten.
14. The endoprosthesis of claim 1, wherein the fibers are visible by magnetic resonance imaging.
15. The endoprosthesis of claim 1, wherein the fibers are invisible by magnetic resonance imaging.
16. The endoprosthesis of claim 1, further comprising a magnetopaque material different than the fibers in the matrix.
17. The endoprosthesis of claim 1 , wherein the tubular member is formed of a plurality of polymeric layers.
18. The endoprosthesis of claim 17, wherein the plurality of polymeric layers includes a layer having fibers oriented substantially longitudinally relative to the tubular member, and a layer having fibers oriented substantially radially relative to the tubular member.
19. The endoprosthesis of claim 1, further comprising a drug-releasing layer on the tubular member.
20. The endoprosthesis of claim 1, wherein the matrix comprises a drug.
21. The endoprosthesis of claim 1 , in the form of a balloon-expandable stent.
22. An endoprosthesis, comprising: a tubular member comprising a polymer; and a first member extending helically around the tubular member, the first member having a stiffhess greater than stiffness of the polymer.
23. The endoprosthesis of claim 22, wherein the first member comprises a metal.
24. The endoprosthesis of claim 22, wherein the first member comprises a polymer.
25. The endoprosthesis of claim 22, wherein the tubular member comprises a plurality of fibers in the polymer, the fibers having a stiffness greater than the stiffhess of the polymer and being substantially oriented in a predetermined direction.
26. The endoprosthesis of claim 22, wherein the polymer encapsulates the first member.
27. An endoprosthesis, comprising: a tubular member having a first layer including a first polymer; and a second layer including a second polymer and a plurality of fibers in the second polymer, the fibers having a stiffhess greater than the stiffness of the polymer and being oriented in a predetermined direction.
28. The endoprosthesis of claim 27, wherein the first layer further includes a plurality of fibers oriented in a predetermined direction.
29. The endoprosthesis of claim 28, wherein the pluralities of fibers in the first and second layers are substantially the same.
30. The endoprosthesis of claim 28, wherein the pluralities of fibers in the first and second layers are oriented in different directions.
31. The endoprosthesis of claim 28, wherein the pluralities of fibers in the first and second layers are oriented in the same direction.
32. The endoprosthesis of claim 27, wherein the first and second polymers are the same polymer.
PCT/US2003/024302 2002-08-28 2003-08-05 Medical devices and methods of making the same WO2004019821A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03791634.3A EP1545394B1 (en) 2002-08-28 2003-08-05 Medical devices
AU2003261349A AU2003261349B2 (en) 2002-08-28 2003-08-05 Medical devices and methods of making the same
JP2004532853A JP2005537090A (en) 2002-08-28 2003-08-05 Medical device and method for manufacturing the same
CA2496576A CA2496576C (en) 2002-08-28 2003-08-05 Medical devices and methods of making the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/229,548 2002-08-28
US10/229,548 US7029495B2 (en) 2002-08-28 2002-08-28 Medical devices and methods of making the same

Publications (1)

Publication Number Publication Date
WO2004019821A1 true WO2004019821A1 (en) 2004-03-11

Family

ID=31976250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024302 WO2004019821A1 (en) 2002-08-28 2003-08-05 Medical devices and methods of making the same

Country Status (6)

Country Link
US (2) US7029495B2 (en)
EP (1) EP1545394B1 (en)
JP (1) JP2005537090A (en)
AU (1) AU2003261349B2 (en)
CA (1) CA2496576C (en)
WO (1) WO2004019821A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046561A1 (en) * 2004-10-26 2006-05-04 Asahi Intecc Co., Ltd. Staying-in-biological body instrument
JP2006520645A (en) * 2003-03-17 2006-09-14 ボストン サイエンティフィック リミテッド Medical instruments

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
FR2812185B1 (en) 2000-07-25 2003-02-28 Spine Next Sa SEMI-RIGID CONNECTION PIECE FOR RACHIS STABILIZATION
FR2812186B1 (en) * 2000-07-25 2003-02-28 Spine Next Sa FLEXIBLE CONNECTION PIECE FOR SPINAL STABILIZATION
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
DE10357334A1 (en) * 2003-12-05 2005-07-07 Grönemeyer, Dietrich H. W., Prof. Dr.med. MR compatible medical implant
US7854756B2 (en) 2004-01-22 2010-12-21 Boston Scientific Scimed, Inc. Medical devices
GB0402736D0 (en) * 2004-02-06 2004-03-10 Tayside Flow Technologies Ltd A drug delivery device
FR2870718B1 (en) * 2004-05-25 2006-09-22 Spine Next Sa TREATMENT ASSEMBLY FOR THE DEGENERATION OF AN INTERVERTEBRAL DISC
US8313524B2 (en) 2004-08-31 2012-11-20 C. R. Bard, Inc. Self-sealing PTFE graft with kink resistance
US7722578B2 (en) * 2004-09-08 2010-05-25 Boston Scientific Scimed, Inc. Medical devices
US8500797B2 (en) * 2004-09-08 2013-08-06 Boston Scientific Scimed, Inc. Medical devices
JP4755189B2 (en) * 2004-10-12 2011-08-24 韓国科学技術院 Content encryption method, network content providing system and method using the same
US20080140187A1 (en) * 2004-10-15 2008-06-12 Krause Arthur A Anti-clotting, anti-microbial, anti-inflammatory medical stent
JP3857295B2 (en) * 2004-11-10 2006-12-13 三菱電機株式会社 Semiconductor light emitting device
US20060121087A1 (en) * 2004-12-06 2006-06-08 Williams Michael S Polymeric endoprostheses with modified erosion rates and methods of manufacture
US7727273B2 (en) * 2005-01-13 2010-06-01 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8083805B2 (en) * 2005-08-16 2011-12-27 Poly-Med, Inc. Absorbable endo-urological devices and applications therefor
US8066759B2 (en) * 2005-02-04 2011-11-29 Boston Scientific Scimed, Inc. Resonator for medical device
US7641983B2 (en) * 2005-04-04 2010-01-05 Boston Scientific Scimed, Inc. Medical devices including composites
US20060259126A1 (en) * 2005-05-05 2006-11-16 Jason Lenz Medical devices and methods of making the same
US7595469B2 (en) * 2005-05-24 2009-09-29 Boston Scientific Scimed, Inc. Resonator for medical device
US20060276875A1 (en) 2005-05-27 2006-12-07 Stinson Jonathan S Medical devices
US20060276910A1 (en) * 2005-06-01 2006-12-07 Jan Weber Endoprostheses
WO2007001472A2 (en) 2005-06-17 2007-01-04 C. R. Bard, Inc. Vascular graft with kink resistance after clamping
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
KR101406415B1 (en) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 Polymer coatings containing drug powder of controlled morphology
US7279664B2 (en) * 2005-07-26 2007-10-09 Boston Scientific Scimed, Inc. Resonator for medical device
US20070038290A1 (en) * 2005-08-15 2007-02-15 Bin Huang Fiber reinforced composite stents
US7304277B2 (en) * 2005-08-23 2007-12-04 Boston Scientific Scimed, Inc Resonator with adjustable capacitor for medical device
US7540997B2 (en) 2005-08-23 2009-06-02 Boston Scientific Scimed, Inc. Medical devices having alloy compositions
US7524282B2 (en) * 2005-08-29 2009-04-28 Boston Scientific Scimed, Inc. Cardiac sleeve apparatus, system and method of use
US20070073374A1 (en) * 2005-09-29 2007-03-29 Anderl Steven F Endoprostheses including nickel-titanium alloys
US7423496B2 (en) * 2005-11-09 2008-09-09 Boston Scientific Scimed, Inc. Resonator with adjustable capacitance for medical device
EP1945138A4 (en) 2005-11-09 2010-02-10 Bard Inc C R Grafts and stent grafts having a radiopaque marker
US7723422B2 (en) * 2005-12-23 2010-05-25 Boston Scientific Scimed, Inc. Functionalized block copolymers
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070203564A1 (en) * 2006-02-28 2007-08-30 Boston Scientific Scimed, Inc. Biodegradable implants having accelerated biodegradation properties in vivo
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
WO2007127363A2 (en) 2006-04-26 2007-11-08 Micell Technologies, Inc. Coatings containing multiple drugs
US20070254012A1 (en) * 2006-04-28 2007-11-01 Ludwig Florian N Controlled degradation and drug release in stents
WO2007149776A2 (en) * 2006-06-20 2007-12-27 Boston Scientific Limited Medical devices including composites
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
WO2008002778A2 (en) 2006-06-29 2008-01-03 Boston Scientific Limited Medical devices with selective coating
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8617045B2 (en) * 2006-08-15 2013-12-31 International Medical Technology, Inc. Urinary incontinence device
JP2010503469A (en) 2006-09-14 2010-02-04 ボストン サイエンティフィック リミテッド Medical device having drug-eluting film
ES2368125T3 (en) 2006-09-15 2011-11-14 Boston Scientific Scimed, Inc. BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS.
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
WO2008033603A2 (en) * 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices having alloy compositions
EP2959925B1 (en) 2006-09-15 2018-08-29 Boston Scientific Limited Medical devices and methods of making the same
EP2066271A1 (en) * 2006-09-18 2009-06-10 Boston Scientific Limited Medical device with porous surface
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
US9585989B2 (en) * 2006-09-19 2017-03-07 Boston Scientific Scimed, Inc. Ureteral stent having variable hardness
WO2008063780A2 (en) 2006-10-12 2008-05-29 C.R. Bard Inc. Vascular grafts with multiple channels and methods for making
US7780798B2 (en) 2006-10-13 2010-08-24 Boston Scientific Scimed, Inc. Medical devices including hardened alloys
CA2667228C (en) * 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
EP2114480B1 (en) * 2006-12-28 2016-01-06 Boston Scientific Limited Medical devices and methods of making the same
EP2277563B1 (en) 2006-12-28 2014-06-25 Boston Scientific Limited Bioerodible endoprostheses and method of making the same
WO2008086369A1 (en) * 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US7972375B2 (en) * 2007-02-05 2011-07-05 Boston Scientific Scimed, Inc. Endoprostheses including metal matrix composite structures
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
NZ580469A (en) * 2007-04-17 2012-05-25 Micell Technologies Inc Coronary stents having biodegradable layers
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
WO2008148013A1 (en) 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US20100070020A1 (en) 2008-06-11 2010-03-18 Nanovasc, Inc. Implantable Medical Device
US20080312694A1 (en) * 2007-06-15 2008-12-18 Peterman Marc M Dynamic stabilization rod for spinal implants and methods for manufacturing the same
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
EP2187988B1 (en) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
WO2009020520A1 (en) 2007-08-03 2009-02-12 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
JP2009082353A (en) * 2007-09-28 2009-04-23 Terumo Corp In-vivo indwelling stent and living organ dilator
US20090093819A1 (en) * 2007-10-05 2009-04-09 Abhijeet Joshi Anisotropic spinal stabilization rod
WO2009051780A1 (en) * 2007-10-19 2009-04-23 Micell Technologies, Inc. Drug coated stents
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8057876B2 (en) * 2008-02-25 2011-11-15 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with layers having different degradation rates
US20090248083A1 (en) * 2008-03-26 2009-10-01 Warsaw Orthopedic, Inc. Elongated connecting element with varying modulus of elasticity
JP5608160B2 (en) 2008-04-17 2014-10-15 ミセル テクノロジーズ、インコーポレイテッド Stent with bioabsorbable layer
WO2009131911A2 (en) 2008-04-22 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
WO2009132176A2 (en) 2008-04-24 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
EP2303350A2 (en) 2008-06-18 2011-04-06 Boston Scientific Scimed, Inc. Endoprosthesis coating
CA2946195A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US20100160968A1 (en) * 2008-12-19 2010-06-24 Abbott Spine Inc. Systems and methods for pedicle screw-based spine stabilization using flexible bands
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
EP2410954A4 (en) * 2009-03-23 2014-03-05 Micell Technologies Inc Peripheral stents having layers
WO2010111232A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
EP2413847A4 (en) 2009-04-01 2013-11-27 Micell Technologies Inc Coated stents
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
CA3186201A1 (en) * 2009-05-20 2010-11-25 Lyra Therapeutics, Inc. Self-expandable medical device comprising polymeric strands and coatings thereon
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc Drug delivery medical device
WO2011017705A2 (en) * 2009-08-07 2011-02-10 University Of Florida Research Foundation, Inc. Magnetic resonance compatible and susceptibility-matched apparatus and method for mr imaging & spectroscopy
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
WO2011059570A1 (en) * 2009-11-12 2011-05-19 Cardiac Pacemakers, Inc. Fiber reinforced silicone for cardiac and neurostimulation leads
US8329219B2 (en) * 2009-12-22 2012-12-11 Cook Biotech Incorporated Methods for producing ECM-based biomaterials
US11369498B2 (en) * 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8721850B2 (en) * 2010-02-02 2014-05-13 Roche Diagnostics Operations, Inc. Biosensor and methods for manufacturing
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US8795762B2 (en) * 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US8696738B2 (en) 2010-05-20 2014-04-15 Maquet Cardiovascular Llc Composite prosthesis with external polymeric support structure and methods of manufacturing the same
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
US20120150142A1 (en) 2010-12-08 2012-06-14 Boston Scientific Scimed, Inc. Drug Eluting Balloons with Ability for Double Treatment
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US9539360B2 (en) * 2011-10-07 2017-01-10 W. L. Gore & Associaes, Inc. Puncturable and resealable graft
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
EP4094725A1 (en) * 2013-03-08 2022-11-30 Carnegie Mellon University Expandable implantable conduit
JP6330024B2 (en) 2013-03-12 2018-05-23 マイセル・テクノロジーズ,インコーポレイテッド Bioabsorbable biomedical implant
JP2016519965A (en) * 2013-05-15 2016-07-11 マイセル・テクノロジーズ,インコーポレイテッド Bioabsorbable biomedical implant
US10751293B2 (en) 2015-09-03 2020-08-25 Case Western Reserve University Polymer fiber scaffolds and uses thereof
US11234840B2 (en) 2016-01-11 2022-02-01 Kambiz Behzadi Bone preparation apparatus and method
US11375975B2 (en) 2016-01-11 2022-07-05 Kambiz Behzadi Quantitative assessment of implant installation
US11241248B2 (en) 2016-01-11 2022-02-08 Kambiz Behzadi Bone preparation apparatus and method
US11109802B2 (en) 2016-01-11 2021-09-07 Kambiz Behzadi Invasive sense measurement in prosthesis installation and bone preparation
US11458028B2 (en) 2016-01-11 2022-10-04 Kambiz Behzadi Prosthesis installation and assembly
US11331069B2 (en) 2016-01-11 2022-05-17 Kambiz Behzadi Invasive sense measurement in prosthesis installation
US11751807B2 (en) 2016-01-11 2023-09-12 Kambiz Behzadi Invasive sense measurement in prosthesis installation and bone preparation
US10251663B2 (en) 2016-01-11 2019-04-09 Kambiz Behzadi Bone preparation apparatus and method
US11298102B2 (en) 2016-01-11 2022-04-12 Kambiz Behzadi Quantitative assessment of prosthesis press-fit fixation
US11534314B2 (en) 2016-01-11 2022-12-27 Kambiz Behzadi Quantitative assessment of prosthesis press-fit fixation
US11399946B2 (en) 2016-01-11 2022-08-02 Kambiz Behzadi Prosthesis installation and assembly
US10864083B2 (en) 2016-04-07 2020-12-15 Kambiz Behzadi Mechanical assembly including exterior surface preparation
US11406504B2 (en) 2016-06-12 2022-08-09 Kambiz Behzadi Mechanical assembly including exterior surface preparation
AU2017371223B2 (en) 2016-12-09 2023-04-27 Zenflow, Inc. Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra
WO2018148722A1 (en) * 2017-02-13 2018-08-16 Rutgers, The State University Of New Jersey Polymer filament reinforced scaffold for partial meniscus regeneration
EP3860825A4 (en) * 2017-09-08 2022-06-15 Zeus Company Inc. Polymeric tubes with controlled orientation
EP3678846A4 (en) * 2017-09-08 2021-06-16 Zeus Industrial Products, Inc. Polymeric tubes with controlled orientation
EP3787554A4 (en) * 2018-04-30 2021-06-16 Board of Regents of the University of Nebraska Stent-graft
JP2023502997A (en) 2019-11-19 2023-01-26 ゼンフロー, インコーポレイテッド Systems, devices and methods for accurate deployment and imaging of implants within the prostatic urethra
US11744702B1 (en) * 2020-07-01 2023-09-05 Aortic Innovations, Llc Transcatheter aortic valve repair and replacement
CN112915255B (en) * 2021-01-20 2021-12-03 浙江大学 Multi-scale biological scaffold and manufacturing method and application thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5195969A (en) 1991-04-26 1993-03-23 Boston Scientific Corporation Co-extruded medical balloons and catheter using such balloons
US5270086A (en) 1989-09-25 1993-12-14 Schneider (Usa) Inc. Multilayer extrusion of angioplasty balloons
US5366504A (en) 1992-05-20 1994-11-22 Boston Scientific Corporation Tubular medical prosthesis
US5565530A (en) 1994-09-12 1996-10-15 Honda Giken Kogyo Kabushiki Kaisha Molecular composite material composed of liquid crystal polymer and method for producing same
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US5780807A (en) 1994-11-28 1998-07-14 Advanced Cardiovascular Systems, Inc. Method and apparatus for direct laser cutting of metal stents
WO1999032051A1 (en) * 1997-12-22 1999-07-01 Impra, Inc. Supported graft and methods of making same
US6066100A (en) 1991-05-23 2000-05-23 Scimed Life Systems, Inc. Intravascular device such as introducer sheath or balloon catheter or the like and methods for use thereof
WO2000038590A1 (en) * 1998-12-23 2000-07-06 Stephen George Edward Barker Endoluminal stent
US6162244A (en) * 1996-03-29 2000-12-19 Willy Ruesch Ag Layered stent
US6340441B1 (en) 1998-03-13 2002-01-22 Scimed Life Systems, Inc. Multi-layer guide wire and method of manufacture therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2636644A1 (en) 1976-08-13 1978-02-16 Maschf Augsburg Nuernberg Ag ENDOPROSTHESIS FOR JOINTS OF THE HUMAN MOTION APPARATUS
CA1147109A (en) * 1978-11-30 1983-05-31 Hiroshi Mano Porous structure of polytetrafluoroethylene and process for production thereof
US5024671A (en) * 1988-09-19 1991-06-18 Baxter International Inc. Microporous vascular graft
US6248129B1 (en) 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US5681572A (en) * 1991-10-18 1997-10-28 Seare, Jr.; William J. Porous material product and process
DE69332950T2 (en) 1992-03-31 2004-05-13 Boston Scientific Corp., Natick BLOOD VESSEL FILTER
ES2166370T3 (en) 1993-01-19 2002-04-16 Schneider Usa Inc IMPLANTABLE FILAMENT IN COMPOSITE MATERIAL.
EP0714270B1 (en) * 1993-08-18 2002-09-04 W.L. Gore & Associates, Inc. A tubular intraluminally insertable graft
EP0738168B1 (en) 1993-10-01 2004-01-21 Boston Scientific Corporation Medical device balloons containing thermoplastic elastomers
US5629077A (en) * 1994-06-27 1997-05-13 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US5709713A (en) * 1995-03-31 1998-01-20 Cardiovascular Concepts, Inc. Radially expansible vascular prosthesis having reversible and other locking structures
US6428571B1 (en) * 1996-01-22 2002-08-06 Scimed Life Systems, Inc. Self-sealing PTFE vascular graft and manufacturing methods
US5733326A (en) 1996-05-28 1998-03-31 Cordis Corporation Composite material endoprosthesis
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6161399A (en) * 1997-10-24 2000-12-19 Iowa-India Investments Company Limited Process for manufacturing a wire reinforced monolayer fabric stent
NL1008093C2 (en) * 1998-01-22 1999-07-26 Hendrik Glastra Sheet material, method of manufacturing it and sleeve-shaped reinforcing element formed using this material.
US6015432A (en) 1998-02-25 2000-01-18 Cordis Corporation Wire reinforced vascular prosthesis
DE69925775T2 (en) 1998-04-06 2006-04-27 Ethicon, Inc. Thermoformable biocompatible absorbable polymeric two-phase matrix for use in medical devices
US6156064A (en) * 1998-08-14 2000-12-05 Schneider (Usa) Inc Stent-graft-membrane and method of making the same
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6406498B1 (en) 1998-09-04 2002-06-18 Bionx Implants Oy Bioactive, bioabsorbable surgical composite material
US6312458B1 (en) * 2000-01-19 2001-11-06 Scimed Life Systems, Inc. Tubular structure/stent/stent securement member
JP2002104914A (en) * 2000-09-22 2002-04-10 Kuraray Co Ltd Method for producing dental material and prosthetic material for dental use
US6913762B2 (en) * 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270086A (en) 1989-09-25 1993-12-14 Schneider (Usa) Inc. Multilayer extrusion of angioplasty balloons
US5195969A (en) 1991-04-26 1993-03-23 Boston Scientific Corporation Co-extruded medical balloons and catheter using such balloons
US6066100A (en) 1991-05-23 2000-05-23 Scimed Life Systems, Inc. Intravascular device such as introducer sheath or balloon catheter or the like and methods for use thereof
US5366504A (en) 1992-05-20 1994-11-22 Boston Scientific Corporation Tubular medical prosthesis
US5565530A (en) 1994-09-12 1996-10-15 Honda Giken Kogyo Kabushiki Kaisha Molecular composite material composed of liquid crystal polymer and method for producing same
US5780807A (en) 1994-11-28 1998-07-14 Advanced Cardiovascular Systems, Inc. Method and apparatus for direct laser cutting of metal stents
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US6162244A (en) * 1996-03-29 2000-12-19 Willy Ruesch Ag Layered stent
WO1999032051A1 (en) * 1997-12-22 1999-07-01 Impra, Inc. Supported graft and methods of making same
US6340441B1 (en) 1998-03-13 2002-01-22 Scimed Life Systems, Inc. Multi-layer guide wire and method of manufacture therefor
WO2000038590A1 (en) * 1998-12-23 2000-07-06 Stephen George Edward Barker Endoluminal stent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520645A (en) * 2003-03-17 2006-09-14 ボストン サイエンティフィック リミテッド Medical instruments
JP4741470B2 (en) * 2003-03-17 2011-08-03 ボストン サイエンティフィック リミテッド Medical instruments
WO2006046561A1 (en) * 2004-10-26 2006-05-04 Asahi Intecc Co., Ltd. Staying-in-biological body instrument

Also Published As

Publication number Publication date
US20040044397A1 (en) 2004-03-04
US20060116755A1 (en) 2006-06-01
EP1545394A1 (en) 2005-06-29
US7029495B2 (en) 2006-04-18
AU2003261349B2 (en) 2008-06-19
US7993391B2 (en) 2011-08-09
AU2003261349A1 (en) 2004-03-19
JP2005537090A (en) 2005-12-08
CA2496576C (en) 2010-11-30
CA2496576A1 (en) 2004-03-11
EP1545394B1 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
CA2496576C (en) Medical devices and methods of making the same
US8048143B2 (en) Medical devices
US6533806B1 (en) Balloon yielded delivery system and endovascular graft design for easy deployment
US8500785B2 (en) Catheter
JP5666295B2 (en) Multi-wire cable catheter
CA2607819C (en) Fiber mesh controlled expansion balloon catheter
AU693357B2 (en) High performance braided catheter
EP1601402B1 (en) Multi-braid exterior tube
US20080221670A1 (en) Radiopaque polymeric stent
US20080178459A1 (en) Method of producing a radially expandable prosthesis
EP1603622A2 (en) Medical devices comprising contrast agent and method of manufacturing
EP1824416B1 (en) Implantable medical endoprosthesis delivery systems
US8221486B2 (en) Laminated stent graft edge binding

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NI NO NZ PG PL PT RO RU SC SD SE SG SK SL TJ TM TR TT TZ UA UG UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2496576

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003791634

Country of ref document: EP

Ref document number: 2004532853

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003261349

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2003791634

Country of ref document: EP